A technology company structured around research into novel therapy(ies) to improve the treatment of eye disease, Lynthera has developed a Drug Delivery Contact Lens (DDCL) structured around the use of nanotechnology to deliver topical eye drops. Offfering significant advantages over currently available systems, the primary focus at this juncture is development of the approach to treat glaucoma. If determined to be effective, the platform has the potential to create a new paradigm of drug delivery that could transform the broader field of eye care.
